The PBS subsidises treatment with idelalisib under the National Health Act 1953, section 85 for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.
Patients must be eligible for the PBS and meet relevant restriction criteria.
Applying for initial treatment
To apply for initial authority approval to prescribe PBS-subsidised idelalisib to treat refractory follicular B-cell non-Hodgkin’s either:
Applying for continuing treatment
Continuing PBS-subsidised treatment with idelalisib is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.
Call the PBS authority approvals line for further information.